Showing 1941-1950 of 2192 results for "".
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Reboxetine Helpful in Obstructive Sleep Apnea Treatmenthttps://practicalneurology.com/news/reboxetine-helpful-in-obstructive-sleep-apnea-treatment/2470118/According to results presented in the Journal of Clinical Sleep Medicine, treatment of obstructive sleep apnea (OSA) with reboxetine (Edronax; Pfizer, New York, NY) was effective at reducing OSA symptom severity. Res
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Cenobamate Reduces Antiseizure Medication Use in Adults With Focal Onset Seizureshttps://practicalneurology.com/news/cenobamate-reduces-antiseizure-medication-use-in-adults-with-focal-onset-seizures/2470080/Adults with focal onset seizures (also known as partial seizures) treated with cenobamate (Xcopri, SK Life Science, Paramus, NJ) experienced a 29% reduction in concomitant antiseizure medication use after 1 year and a 32% reduction after 2 years, according to research presented at the American Ep
- Study Finds Evidence of Link Between Absence Seizures and Myelin Plasticityhttps://practicalneurology.com/news/study-finds-evidence-of-link-between-absence-seizures-and-myelin-plasticity/2470079/Results from a novel study presented at the American Epilepsy Society Annual Meeting revealed an association between seizures and myelin plasticity, opening exciting possibilities for future research. Researchers documented an increase in both the total number of myelinated fibers as well as thic
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A
- First Participant in Phase 2/3 study of Trehalose Injection in Spinocerebellar Ataxiahttps://practicalneurology.com/news/first-participant-in-phase-23-study-of-trehalose-injection-in-spinocerebellar-ataxia/2470055/In the STRIDES study (NCT05490563), the first participant received a dose of 90.5 mg/mL trehalose injection (SLS-005; Seelos Therapeutics, New York, NY) for the treatment of type 3 spinocerebellar
- Tofersen Slowed Decline SOD1-Associated Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/tofersen-slowed-decline-sod1-associated-amyotrophic-lateral-sclerosis/2470036/In the phase 3 VALOR study (NCT02623699), participants with superoxide dismutase 1 (SOD1)-associated amyotrophic lateral sclerosis (ALS) had slowed disease progression when treated with tofersen (